Online citations, reference lists, and bibliographies.

Chemotherapy For Intraperitoneal Use: A Review Of Hyperthermic Intraperitoneal Chemotherapy And Early Post-operative Intraperitoneal Chemotherapy.

Martin D. Goodman, Sarah J. McPartland, Danielle Detelich, Muhammad Wasif Saif
Published 2016 · Medicine
Cite This
Download PDF
Analyze on Scholarcy
Share
Peritoneal spread of tumors is a major problem in cancer management. Patients develop a marked deterioration in quality of life and shortened survival. This is in part due to bowel obstructions, marked ascites, and overall increase debilitation. Standard medical management has shown to be inadequate for the treatment of these problems. Surgery can palliate symptoms, however, it is unable to be complete at the microscopic level by a significant spillage of tumor cells throughout the abdomen. Chemotherapy can have some improvement in symptoms however it is short lived due to poor penetration into the peritoneal cavity. The role of intraperitoneal chemotherapy is to maximize tumor penetration and optimize cell death while minimizing systemic toxicity. Hyperthermic intraperitoneal chemotherapy (HIPEC) and early post-operative intraperitoneal chemotherapy (EPIC) are two treatment methods that serve this role and have been shown to improve survival. This review will discuss different chemotherapies used for both of these treatment options.
This paper references
Relationship between area of serosal invasion and intraperitoneal free cancer cells in patients with gastric cancer.
Masahide Ikeguchi (1994)
10.1002/jso.21324
Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery.
Yutaka Yonemura (2009)
10.1245/s10434-009-0878-6
Cytoreduction and Hyperthermic Intraperitoneal Chemoperfusion in Women with Heavily Pretreated Recurrent Ovarian Cancer
PhD Facs Wim P. Ceelen MD (2009)
10.1056/NEJMoa032691
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.
Herbert I. Hurwitz (2004)
10.1002/cncr.23553
Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer.
Angelo di Giorgio (2008)
10.1245/s10434-015-4679-9
Mitomycin C Pharmacokinetics as Predictor of Severe Neutropenia in Hyperthermic Intraperitoneal Therapy
Véronique Kemmel (2015)
10.1002/jso.21084
Treatment failure following complete cytoreductive surgery and perioperative intraperitoneal chemotherapy for peritoneal dissemination from colorectal or appendiceal mucinous neoplasms.
Lana Bijelić (2008)
10.1002/jso.21682
Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer.
Franco Roviello (2010)
10.1200/JCO.2006.09.2684
Phase III study of capecitabine plus oxaliplatin compared with fluorouracil and leucovorin plus oxaliplatin in metastatic colorectal cancer: a final report of the AIO Colorectal Study Group.
Rainer Porschen (2007)
10.5005/jp/books/11667_1
Chapter-01 Pathophysiology of Peritoneal Malignancies and Modalities of Treatment
Sarah McPartland (2012)
10.1007/978-1-4613-1245-1_6
Surgically directed chemotherapy: heated intraperitoneal lavage with mitomycin C.
Vicente Fernandez-Trigo (1996)
10.1093/annonc/mdf019
Heated intra-operative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution.
Dominique M Elias (2002)
10.1002/ijc.24290
Recent patterns in gastric cancer: a global overview.
Paola Bertuccio (2009)
10.1053/j.seminoncol.2011.05.011
Management of peritoneal carcinomatosis from colorectal cancer.
Chukwuemeka U. Ihemelandu (2011)
Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. A manual for physicians and nurses
(1998)
10.1016/S1055-3207(03)00031-0
Pharmacokinetics of intraperitoneal mitomycin C.
Serge van Ruth (2003)
10.1007/s002800000214
Impact of carrier solutions on pharmacokinetics of intraperitoneal chemotherapy
Sophie R Pestieau (2001)
10.1016/j.ygyno.2011.04.008
HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome.
Anna Fagotti (2011)
10.1200/JCO.2005.07.113
Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.
G. P. Colucci (2005)
10.1093/annonc/mdq164
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Alicia Okines (2010)
10.3322/caac.20138
Cancer statistics, 2012.
Rebecca L Siegel (2012)
10.1002/jso.23633
Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSSA trial.
Udo Rudloff (2014)
10.1245/s10434-008-0073-1
Hyperthermic Intraperitoneal Chemotherapy with Oxaliplatin for Peritoneal Carcinomatosis Arising from Appendix: Preliminary Results of a Survival Analysis
Eric Marcotte (2008)
10.1002/cncr.25640
A novel tumor-node-metastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database*.
Tristan D. Yan (2011)
10.1159/000324667
Immunotherapy of Peritoneal Carcinomatosis with the Antibody Catumaxomab in Colon, Gastric, or Pancreatic Cancer: An Open-Label, Multicenter, Phase I/II Trial
Michael Alfred Ströhlein (2011)
10.1245/s10434-007-9718-8
Phase I Trial of Pegylated Liposomal Doxorubicin with Hyperthermic Intraperitoneal Chemotherapy in Patients Undergoing Cytoreduction for Advanced Intra-abdominal Malignancy
Lawrence E. Harrison (2007)
10.1002/(SICI)1097-0142(20000115)88:2<358::AID-CNCR16>3.0.CO;2-O
Peritoneal carcinomatosis from non-gynecologic malignancies: results of the EVOCAPE 1 multicentric prospective study.
B Sadeghi (2000)
10.1159/000136874
Transport of model compounds across the peritoneal membrane in the rat.
I. Junco Torres (1978)
10.1016/S0378-4274(00)00201-0
Intraperitoneal administration of doxorubicin encapsulating liposomes against peritoneal dissemination.
Yasuyuki Sadzuka (2000)
Perioperative 54
TD Yan (2006)
Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early postoperative intraperitoneal chemotherapy
M D Goodman (2016)
10.1186/1479-5876-4-17
Perioperative intraperitoneal chemotherapy for peritoneal surface malignancy
Tristan D. Yan (2006)
10.1016/j.ejso.2010.01.006
Pseudomyxoma peritonei: a French multicentric study of 301 patients treated with cytoreductive surgery and intraperitoneal chemotherapy.
Dominique M Elias (2010)
Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally cyto-reduced, recurrent, platinum sensitive ovarian carcinoma: A pilot study
PA Argenta (2016)
10.1634/theoncologist.10-2-112
Update on chemotherapeutic agents utilized for perioperative intraperitoneal chemotherapy.
Paul H Sugarbaker (2005)
10.1053/ctrv.2001.0232
Rationale and techniques of intra-operative hyperthermic intraperitoneal chemotherapy.
Arjen J Witkamp (2001)
Clinical delivery system for intraperitoneal hyperthermic chemotherapy.
John S. Spratt (1980)
10.1245/s10434-006-9169-7
Prognostic Indicators for Patients Undergoing Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma†
Tristan D. Yan (2006)
10.1007/s10434-999-0790-0
Morbidity and Mortality Analysis of 200 Treatments With Cytoreductive Surgery and Hyperthermic Intraoperative Intraperitoneal Chemotherapy Using the Coliseum Technique
Arvil D. Stephens (1999)
10.1016/j.ejso.2010.04.005
Hyperthermic intra-peritoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial. CHIPOVAC study.
Christophe Pomel (2010)
10.1097/00000658-199501000-00004
Peritonectomy Procedures
Paul H Sugarbaker (2003)
10.1007/s10434-004-1167-z
Long-Term Survival of Peritoneal Carcinomatosis of Colorectal Origin
Vic J. Verwaal (2004)
Carcinomatosis for colon Cancer
TC Chua
Hyperthermic intraperitoneal chemotherapy using oxaliplatin as consolidation therapy for advanced epithelial ovarian carcinoma. Results of a phase II prospective multicentre trial
C Pomel (2010)
10.1007/s10434-006-9708-2
Appendiceal Neoplasms With Peritoneal Dissemination: Outcomes After Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy
John H. Stewart (2006)
10.1007/s002920050340
Peritoneale Mesotheliome – Häufigkeiten und Ätiologie
V. Neumann (1999)
10.1200/JCO.2008.19.7160
Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin.
Dominique Elias (2009)
10.1016/j.ygyno.2013.01.010
Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study.
Peter A. Argenta (2013)
10.1016/j.ygyno.2006.10.051
Hyperthermic intraperitoneal chemotherapy in conjunction with surgery for the treatment of recurrent ovarian carcinoma.
C. William Helm (2007)
10.1245/ASO.2003.01.018
Intraperitoneal Chemohyperthermia Using a Closed Abdominal Procedure and Cytoreductive Surgery for the Treatment of Peritoneal Carcinomatosis: Morbidity and Mortality Analysis of 216 Consecutive Procedures
Olivier Gléhen (2003)
10.1097/00000478-200308000-00006
Appendiceal Mucinous Neoplasms: A Clinicopathologic Analysis of 107 Cases
Joseph Misdraji (2003)
10.1200/JCO.2009.23.9285
Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study.
Dominique M Elias (2010)
Prospective trial for the treatment of malignant peritoneal mesothelioma.
Brian W. Loggie (2001)
10.2165/00003088-200443020-00005
Population Pharmacokinetics and Pharmacodynamics of Mitomycin During Intraoperative Hyperthermic Intraperitoneal Chemotherapy
S. van Ruth (2004)
10.1056/NEJM199612263352603
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.
David S. Alberts (1996)
10.1007/BF01225271
Efficacy of cisplatin-based intraperitoneal chemotherapy as treatment of malignant peritoneal mesothelioma
Maurie Markman (2005)
10.1002/ijc.25423
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial
Markus Maria Heiss (2010)
A novel tumor-nodemetastasis (TNM) staging system of diffuse malignant peritoneal mesothelioma using outcome analysis of a multi-institutional database. Cancer 2011;117:1855-63
TD Yan (2011)
10.1007/s10434-999-0727-7
Results of Treatment of 385 Patients With Peritoneal Surface Spread of Appendiceal Malignancy
Paul H Sugarbaker (1999)
10.1002/jso.21051
Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy.
Shigeki Kusamura (2008)
Carcinomatosis for colon Cancer. In: Goodman MD, editor. Regional Therapeutics for Advanced Malignancies
TC Chua (2012)
10.1245/ASO.2006.03.045
Prognostic Analysis of Clinicopathologic Factors in 49 Patients With Diffuse Malignant Peritoneal Mesothelioma Treated With Cytoreductive Surgery and Intraperitoneal Hyperthermic Perfusion
Marcello Deraco (2006)
10.1200/JCO.2007.14.9898
Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.
Jim Cassidy (2008)
10.1245/s10434-008-0105-x
Multivisceral Resection Does Not Affect Morbidity and Survival After Cytoreductive Surgery and Chemoperfusion for Carcinomatosis from Colorectal Cancer
Jan Franko (2008)
10.1016/J.JAMCOLLSURG.2011.06.324
Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: A systematic review of survival, mortality and morbidity
Richdeep S Gill (2011)
Post-operative chemotherapy in non-curative gastrectomy for advanced gastric cancer.
Kazuhiro Hanazaki (1999)
10.1097/COC.0b013e3180684181
Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for the Treatment of Malignant Peritoneal Mesothelioma
Mary Hesdorffer (2008)
10.1245/s10434-008-0127-4
Peritoneal Surface Disease from Colorectal Cancer: Comparison with the Hepatic Metastases Surgical Paradigm in Optimally Resected Patients
Perry Shen (2008)
10.1245/s10434-008-0299-y
Hyperthermic Intraperitoneal Chemotherapy After Extensive Cytoreductive Surgery in Patients with Primary Advanced Epithelial Ovarian Cancer: Interim Analysis of a Phase II Study
Myong Cheol Lim (2008)
Determinants of paclitaxel penetration and accumulation in human solid tumor.
Hyo Jeong Kuh (1999)
10.1097/00000478-199710000-00004
The morphologic spectrum of ovarian metastases of appendiceal adenocarcinomas: a clinicopathologic and immunohistochemical analysis of tumors often misinterpreted as primary ovarian tumors or metastatic tumors from other gastrointestinal sites.
B M Ronnett (1997)
10.1245/ASO.2004.07.002
Peritonectomy and Intraperitoneal Hyperthermic Perfusion (IPHP): A Strategy That Has Confirmed its Efficacy in Patients with Pseudomyxoma Peritonei
Marcello Deraco (2004)
10.1002/cncr.25356
Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients.
Olivier Glehen (2010)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
Marie-Paule Sablin (2010)
Early postoperative intraperitoneal chemotherapy as an adjuvant therapy to surgery for peritoneal carcinomatosis from gastrointestinal cancer: pharmacological studies.
Paul H Sugarbaker (1990)
10.1038/bjc.1995.114
Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer.
Seppo O. Pyrhönen (1995)
10.1245/s10434-008-9967-1
A Phase I Trial of Oxaliplatin for Intraperitoneal Hyperthermic Chemoperfusion for the Treatment of Peritoneal Surface Dissemination from Colorectal and Appendiceal Cancers
John H. Stewart (2008)
10.1200/JCO.2007.14.9930
Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.
Leonard B Saltz (2008)
10.1200/JCO.2004.10.012
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study.
Olivier Glehen (2004)
10.3322/canjclin.39.6.399
Cancer statistics.
N Dubrawsky (1989)
10.1016/j.ygyno.2005.11.013
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study.
Joan L. Walker (2006)
10.1155/2012/148420
Effects of Neoadjuvant Intraperitoneal/Systemic Chemotherapy (Bidirectional Chemotherapy) for the Treatment of Patients with Peritoneal Metastasis from Gastric Cancer
Yutaka Yonemura (2012)
10.3748/WJG.14.6817
Cytoreduction and hyperthermic intraperitoneal chemotherapy in the treatment of peritoneal carcinomatosis from pseudomyxoma peritonei.
Tommaso Cioppa (2008)
10.1245/s10434-009-0487-4
A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin
Christopher Cao (2009)
10.1007/978-1-4613-1247-5_6
Observations concerning cancer spread within the peritoneal cavity and concepts supporting an ordered pathophysiology.
Paul H Sugarbaker (1996)
Management of peritoneal surface malignancy using intraperitoneal chemotherapy and cytoreductive surgery. A manual for physicians and nurses, third edition
PH Sugarbaker (1998)
10.1007/978-1-4613-1245-1_2
Early postoperative intraperitoneal Adriamycin as an adjuvant treatment for visceral and retroperitoneal sarcoma.
Paul H Sugarbaker (1996)
10.1200/JCO.2003.04.187
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer.
Vic J. Verwaal (2003)
10.1007/s10350-005-0045-5
Cytoreductive Surgery With Intraperitoneal Chemohyperthermia for the Treatment of Pseudomyxoma Peritonei: A Prospective Study
Rasmy Loungnarath (2005)
10.1053/ejso.2002.1397
A comparison of hetastarch and peritoneal dialysis solution for intraperitoneal chemotherapy delivery.
Faheez Mohamed (2003)
10.1016/j.ygyno.2011.05.004
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial.
Marcello Deraco (2011)
10.1016/j.ygyno.2007.03.019
Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery.
Jeong Hoon Bae (2007)
Heated intraoperative intraperitoneal oxaliplatin after complete resection of peritoneal carcinomatosis: pharmacokinetics and tissue distribution
D Elias (2002)
10.4251/wjgo.v2.i2.85
Multidisciplinary therapy for treatment of patients with peritoneal carcinomatosis from gastric cancer.
Yutaka Yonemura (2010)
10.1155/2012/358341
Cytoreductive Surgery Combined with Hyperthermic Intraperitoneal Intraoperative Chemotherapy in the Treatment of Advanced Epithelial Ovarian Cancer
Antonios-Apostolos K Tentes (2012)
10.5005/JP/BOOKS/11667
Regional Therapeutics for Advanced Malignancies
D. G. Martin (2012)
[Peritoneal mesothelioma--incidence and etiology].
Víctor Neumann (1999)
Pathophysiology of Peritoneal Malignancies and Modalities of Treatment. In: Goodman MD, editor. Regional Therapeutics for Advanced Malignancies
S Mcpartland (2012)
Randomized comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer
S Pyrhönen (1995)
10.1002/jso.22017
Treatment of gastric cancer with peritoneal carcinomatosis by cytoreductive surgery and HIPEC: a systematic review of survival, mortality, and morbidity.
Richdeep S Gill (2011)
10.1245/ASO.2006.05.041
Peritoneal Mesothelioma Treated by Cytoreductive Surgery and Intraperitoneal Hyperthermic Chemotherapy: Results of a Prospective Study
Cécile Brigand (2006)
10.1097/01.sla.0000255561.87771.11
Iterative Cytoreductive Surgery Associated With Hyperthermic Intraperitoneal Chemotherapy for Treatment of Peritoneal Carcinomatosis of Colorectal Origin With or Without Liver Metastases
Réza Kianmanesh (2007)
10.1002/(SICI)1096-9098(199901)70:1<6::AID-JSO2>3.0.CO;2-X
Clinical picture, response to therapy, and survival of women with diffuse malignant peritoneal mesothelioma.
Gamal H. Eltabbakh (1999)
10.1007/s00268-007-9146-8
Cytoreductive Surgery and Intraperitoneal Chemohyperthermia for Chemoresistant and Recurrent Advanced Epithelial Ovarian Cancer: Prospective Study of 81 Patients
Eddy Cotte (2007)
10.1200/JCO.2006.07.1142
Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma.
Tristan D. Yan (2006)
10.1056/NEJM200009283431302
Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group.
Leonard B Saltz (2000)
ombined resection, intraperitoneal chemotherapy, and whole abdominal radiation for the treatment of malignant peritoneal mesothelioma
ME Hesdorffer (2008)
10.1200/JCO.2001.19.4.1001
Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Gr
Margaret R Markman (2001)
10.1046/j.1365-2168.2001.01701.x
Extensive surgical cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in patients with pseudomyxoma peritonei.
Arjen J Witkamp (2001)
10.1155/2014/912418
The Treatment of Peritoneal Carcinomatosis in Advanced Gastric Cancer: State of the Art
Giulia Montori (2014)
10.1097/01.sla.0000231705.40081.1a
Survival Analysis of Pseudomyxoma Peritonei Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Robert M. Smeenk (2007)
10.1016/j.ygyno.2007.03.022
Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma.
Samuel S. Lentz (2007)
10.1245/s10434-009-0756-2
Lymph Node Metastases in Diffuse Malignant Peritoneal Mesothelioma
Dario Baratti (2009)
10.1200/JCO.2009.23.9640
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience.
Tristan D. Yan (2009)
10.1016/S1040-8428(01)00179-2
The cellular and molecular basis of hyperthermia.
Bert Hildebrandt (2002)
10.1200/JCO.2003.04.150
Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy.
Andrew L. Feldman (2003)
10.1056/NEJMoa052985
Intraperitoneal cisplatin and paclitaxel in ovarian cancer.
Deborah Kay Armstrong (2006)
10.4251/wjgo.v2.i2.109
A pharmacological review on intraperitoneal chemotherapy for peritoneal malignancy.
Tristan D. Yan (2010)
10.1007/s00268-009-0059-6
Significance of Lymph Node Metastasis in Patients with Colorectal Cancer Peritoneal Carcinomatosis
Terence C Chua (2009)



This paper is referenced by
10.1016/j.suronc.2017.04.001
Is hyperthermic intraperitoneal chemotherapy (HIPEC) safe for healthcare workers?
Simon Rodier (2017)
Modeling of drug delivery and transport during intraperitoneal chemotherapy
Margo Steuperaert (2019)
10.1002/marc.201800007
Cholesterol Modification of an Anticancer Drug for Efficient Incorporation into a Supramolecular Hydrogel System.
Maarten H Bakker (2018)
10.1016/j.jconrel.2017.06.005
Targeting of p32 in peritoneal carcinomatosis with intraperitoneal linTT1 peptide‐guided pro‐apoptotic nanoparticles
Hedi Hunt (2017)
10.1590/s0102-865020200050000004
The influence of platelet-rich plasma (PRP) on colonic anastomosis healing impaired by intraperitoneal 5-flourouracil application. An experimental study
Mustafa Gorur (2020)
10.18632/oncotarget.26667
Body surface area-based versus concentration-based intraperitoneal perioperative chemotherapy in a rat model of colorectal peritoneal surface malignancy: pharmacologic guidance towards standardization
Lieselotte Lemoine (2019)
10.1016/j.xphs.2017.10.008
Suitability of the AUC Ratio as an Indicator of the Pharmacokinetic Advantage in HIPEC.
María Isabel Mas-Fuster (2018)
10.1016/j.ejso.2019.03.036
Systemic inflammatory response after hyperthermic intraperitoneal chemotherapy (HIPEC): The perfusion protocol matters!
Lilian Roth (2019)
10.3390/cancers11010078
Variation in Clinical Application of Hyperthermic Intraperitoneal Chemotherapy: A Review
Roxan F C P A Helderman (2019)
10.3390/cancers11111662
Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer
Adriana C. Gamboa (2019)
10.1111/ajco.13275
Hematological toxicities associated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Evelyn Y T Wong (2019)
10.1002/wnan.1451
Nanoparticle drug-delivery systems for peritoneal cancers: a case study of the design, characterization and development of the expansile nanoparticle.
Aaron H. Colby (2017)
10.2147/GICTT.S139944
Current perspectives on hyperthermic intraperitoneal chemotherapy in gastric cancer
S. Desmond Smith (2017)
10.1515/pp-2016-0022
Pharmacokinetic problems in peritoneal drug administration: an update after 20 years
Michael Francis Flessner (2016)
10.1245/s10434-020-08743-9
Systemic Pharmacokinetics of Oxaliplatin After Intraperitoneal Administration by Electrostatic Pressurized Intraperitoneal Aerosol Chemotherapy (ePIPAC) in Patients with Unresectable Colorectal Peritoneal Metastases in the CRC-PIPAC Trial
Robin J. Lurvink (2020)
10.1245/s10434-018-6499-1
Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival
Vivek Verma (2018)
10.4081/joper.2018.104
The effect of hyperthermia (42°C) on the anti-tumoral effect of bromelain, N-acetyl cysteine, chemotherapeutic agents and their combinations - an in vitro evaluation
Vanessa H.L. Wan (2018)
10.2967/jnumed.118.208611
Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer
Emmanuel Deshayes (2018)
10.17925/ohr.2019.15.2.83
Hypothermic Intraperitoneal Chemotherapy for Gastrointestinal Malignancies—A Relic of the Past or Useful Tool for Today?
Megan Greally (2019)
10.18632/oncotarget.16480
Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy
James McMullen (2017)
10.1245/s10434-020-08844-5
Defining “Complete Cytoreduction” After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC) for the Histopathologic Spectrum of Appendiceal Carcinomatosis
Carlos A Muñoz-Zuluaga (2020)
Effect of S-1 combined with cisplatin intraperitoneal circulatory hyperthermia perfusion treatment on malignant molecule expression in gastric cancer patients with ascites as well as side effect assessment
Shuo Jian (2016)
10.1002/pbc.27517
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A safe treatment option for intraperitoneal rhabdomyosarcoma in children below 5 years of age.
Jens Gesche (2019)
10.3762/bjnano.8.132
Carbon nanomaterials sensitize prostate cancer cells to docetaxel and mitomycin C via induction of apoptosis and inhibition of proliferation
Kati Erdmann (2017)
10.1007/s12029-018-0161-9
A Modified Low-Cost Technique of Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Two Patients: a Solution for Pseudomyxoma Peritonei in the Indian Scenario?
Anil Kumar Singh Rana (2018)
10.1007/978-3-030-35252-3_6
Fluid Dynamics in Healthcare Industries: Computational Intelligence Prospective
Vishwanath Panwar (2020)
10.1007/978-3-030-28891-4_7
Rationale Behind HIPEC/Molecular and Genetic Considerations in HIPEC
Jula Veerapong (2020)
10.1080/10717544.2019.1588423
A 3D CFD model of the interstitial fluid pressure and drug distribution in heterogeneous tumor nodules during intraperitoneal chemotherapy
Margo Steuperaert (2019)
10.3389/fonc.2020.00819
Integrating Loco-Regional Hyperthermia Into the Current Oncology Practice: SWOT and TOWS Analyses
Niloy Ranjan Datta (2020)
10.3390/molecules23051190
Peritoneal Carcinomatosis Targeting with Tumor Homing Peptides
Lorena Simón-Gracia (2018)
10.1016/j.jss.2019.10.042
Cytoreductive Surgery and HIPEC in an Enhanced Recovery After Surgery Program: A Feasibility Study.
Pamela W. Lu (2019)
10.1155/2020/9107140
Increased Temperature Facilitates Adeno-Associated Virus Vector Transduction of Colorectal Cancer Cell Lines in a Manner Dependent on Heat Shock Protein Signature
Alicja Bieńkowska (2020)
See more
Semantic Scholar Logo Some data provided by SemanticScholar